231 related articles for article (PubMed ID: 9012554)
41. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects.
Müller P; Flesch G; de Gasparo M; Gasparini M; Howald H
Eur J Clin Pharmacol; 1997; 52(6):441-9. PubMed ID: 9342579
[TBL] [Abstract][Full Text] [Related]
42. Clinical pharmacology of multiple-dose losartan, an angiotensin II receptor antagonist, in patients with essential hypertension.
Sasaki M; Fujimura A; Harada K; Sunaga K; Ebihara A
J Clin Pharmacol; 1996 May; 36(5):403-8. PubMed ID: 8739018
[TBL] [Abstract][Full Text] [Related]
43. A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity.
Arsenault J; Lehoux J; Lanthier L; Cabana J; Guillemette G; Lavigne P; Leduc R; Escher E
Pharmacogenet Genomics; 2010 Jun; 20(6):377-88. PubMed ID: 20436376
[TBL] [Abstract][Full Text] [Related]
44. [ARB: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
Mitsuyama S
Nihon Rinsho; 2007 May; 65 Suppl 5():78-83. PubMed ID: 17571369
[No Abstract] [Full Text] [Related]
45. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects.
Müller P; Cohen T; de Gasparo M; Sioufi A; Racine-Poon A; Howald H
Eur J Clin Pharmacol; 1994; 47(3):231-45. PubMed ID: 7867676
[TBL] [Abstract][Full Text] [Related]
46. Angiotensin II receptor antagonists versus angiotensin converting enzyme inhibitors: effects on renal function.
Jover B; Mimran A
J Hypertens Suppl; 1994 Nov; 12(9):S3-9. PubMed ID: 7884582
[TBL] [Abstract][Full Text] [Related]
47. [Hormonal contribution to short-term variability of blood pressure in a renovascular hypertension model].
Ponchon P; Elghozi JL
Arch Mal Coeur Vaiss; 1995 Aug; 88(8):1203-7. PubMed ID: 8572874
[TBL] [Abstract][Full Text] [Related]
48. [Nonpeptide angiotensin II receptor antagonists].
Nishikawa K
Tanpakushitsu Kakusan Koso; 1993 Aug; 38(11):1873-80. PubMed ID: 8210431
[No Abstract] [Full Text] [Related]
49. In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist.
Siegl PK; Chang RS; Mantlo NB; Chakravarty PK; Ondeyka DL; Greenlee WJ; Patchett AA; Sweet CS; Lotti VJ
J Pharmacol Exp Ther; 1992 Jul; 262(1):139-44. PubMed ID: 1625193
[TBL] [Abstract][Full Text] [Related]
50. Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans.
Coltamai L; Maillard M; Simon A; Vogt B; Burnier M
J Hypertens; 2010 Mar; 28(3):520-6. PubMed ID: 20104189
[TBL] [Abstract][Full Text] [Related]
51. Angiotensin II receptor inhibition. A new therapeutic principle.
Messerli FH; Weber MA; Brunner HR
Arch Intern Med; 1996 Sep; 156(17):1957-65. PubMed ID: 8823149
[TBL] [Abstract][Full Text] [Related]
52. Angiotensin II blockade compared with other pharmacological methods of inhibiting the renin-angiotensin system.
Brunner HR; Nussberger J; Waeber B
J Hypertens Suppl; 1993 Apr; 11(3):S53-8. PubMed ID: 8315521
[TBL] [Abstract][Full Text] [Related]
53. Angiotensin receptor antagonists.
Wong W; Howes L
Aust Fam Physician; 2000 Jul; 29(7):653-5, 658. PubMed ID: 10914449
[TBL] [Abstract][Full Text] [Related]
54. How well have animal studies with losartan predicted responses in humans?
Sweet CS; Nelson EB
J Hypertens Suppl; 1993 Apr; 11(3):S63-7. PubMed ID: 8315522
[TBL] [Abstract][Full Text] [Related]
55. Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect?
Ernsberger P; Koletsky RJ
Curr Opin Pharmacol; 2007 Apr; 7(2):140-5. PubMed ID: 17303473
[TBL] [Abstract][Full Text] [Related]
56. [Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].
Sidorenko BA; Preobrazhenskiĭ DV; Soplevenko AV; Ivanova NA; Stetsenko TM
Kardiologiia; 2004; 44(1):55-65. PubMed ID: 15029149
[TBL] [Abstract][Full Text] [Related]
57. Clinical experience with angiotensin II receptor antagonists.
Lee RJ; Brunner HR
J Hum Hypertens; 1993 Aug; 7 Suppl 2():S33-6. PubMed ID: 8230087
[TBL] [Abstract][Full Text] [Related]
58. The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations.
Brunner HR
Am J Hypertens; 1997 Dec; 10(12 Pt 2):311S-317S. PubMed ID: 9438775
[TBL] [Abstract][Full Text] [Related]
59. Clinical pharmacokinetics of vasodilators. Part I.
Kirsten R; Nelson K; Kirsten D; Heintz B
Clin Pharmacokinet; 1998 Jun; 34(6):457-82. PubMed ID: 9646008
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of the angiotensin challenge methodology for assessing the pharmacodynamic profile of antihypertensive drugs acting on the renin-angiotensin system.
Buchwalder-Csajka C; Buclin T; Brunner HR; Biollaz J
Br J Clin Pharmacol; 1999 Oct; 48(4):594-604. PubMed ID: 10583031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
